Clinical Trial Research Agreement Sample Contracts
CLINICAL TRIAL RESEARCH AGREEMENT SMLOUVA O PROVEDENÍ KLINICKÉHOClinical Trial Research Agreement • November 26th, 2024
MERCK SHARP & DOHME s.r.o., with its address at Na Valentince 3336/4, Prague 5, Zip code 150 00, ID: 284 62 564, tax ID: CZ 284 62 564, registered in the Companies Register maintained by the Municipal Court in Prague (Section C, File No. 143294), acting in its own name at the request of Merck Sharp & Dohme LLC with its address at 126 East Lincoln Avenue, P.O. Box 2000, Rahway, NJ 07065 United States of America (hereinafter called “Sponsor”),
Clinical Trial Research AgreementClinical Trial Research Agreement • March 7th, 2025
The body of this Agreement (that is from the following page to the execution clauses) is changes intended to be identical to the standard form a copy of which is located at must http://medicinesaustralia.com.au/issues-information/clinical-trials/clinical-trials-research- have agreements. Any textual change to the body of this Agreement is to be ignored, and SEBS reference instead had to the standard form, as amended by Schedule 7 by way of Special approval Conditions.
ContractClinical Trial Research Agreement • January 21st, 2019
CLINICAL TRIAL RESEARCH AGREEMENT(For Use in the Czech Republic) This Agreement is entered into as of the last date on the signature page hereof, by and among FAKULTNÍ NEMOCNICE OSTRAVA, with its address at17. listopadu 1790, zipcode: 708 52, Ostrava-Poruba, Czech Republic, company ID: 008 43 989, Tax ID: CZ00843989, Deed of foundation of the Ministry of Health of the Czech Republic from 25 November 1990 ref. No. OP-054-25.11.90, bank details: Česká národní banka, account number: 66332761/0710, IBAN: CZ59 0710 0000 0000 6633 2761, BIC code (SWIFT): CNBACZPP, variable symbol: 649071198, represented by,(hereinafter called "Institution) andMERCK SHARP & DOHME, s.r.o., with its address at Na Valentince 3336/4, Prague 5, ZIP code 150 00, ID: 284 62 564, tax ID: CZ 284 62 564, registered in the Companies Register maintained by the Municipal Court in Prague (Section C, File No. 143 294), acting in its own name at the request of Merck Sharp & Dohme Corp. with its address at 1 Merck Drive, Whit
Clinical Trial Research Agreement Medicines Australia CTRA: Contract Research Organisation acting as the Local SponsorClinical Trial Research Agreement • November 9th, 2021
This agreement is to be used where a Contract Research Organisation acts as, and assumes all of the responsibilities of, a local commercial sponsor.
Clinical Trial Research AgreementClinical Trial Research Agreement • November 9th, 2021
The body of this Agreement (that is from the following page to the execution clauses) is intended to be identical to the standard form a copy of which is located at http://medicinesaustralia.com.au/issues-information/clinical-trials/clinical-trials-research-agreements. Any textual change to the body of this Agreement is to be ignored, and reference instead had to the standard form, as amended by Schedule 4 by way of Special Conditions.
Clinical Trial Research Agreement Investigator-Initiated, Company Supported StudiesClinical Trial Research Agreement • October 14th, 2022
The body of the Agreement is not to be amended. Revisions are to be detailed in Schedule 3 with appropriate cross-referencing to the relevant section of the Agreement.
CLINICAL TRIAL RESEARCH AGREEMENTClinical Trial Research Agreement • September 22nd, 2017
Šrobárova 1150/50, Prague 10, Zip codeL 100 34, company ID: 00064173, Tax ID: CZ00064173, bank details Česká národní banka, account number XXX, represented by Doc. MUDr. Robert Grill Ph.D. MHA, Director, Reference no.: KH28/2017, centre cost: 51035 (hereinafter called "Provider"),
Clinical Trial Research Agreement For an Investigator Initiated StudyClinical Trial Research Agreement • September 27th, 2022
This document has been password-protected to ensure the integrity of the document. Text can be inserted in the table below as well as into Schedules 1 to 4 (inclusive). Schedule 4 is available for text insertion or the inclusion of any additional information such as tables and spreadsheets by way of Special Conditions.
CERTAIN CONFIDENTIAL INFORMATION IN THIS EXHIBIT WAS OMITTED BY MEANS OF MARKING SUCH INFORMATION WITH BRACKETS (“[***]”) BECAUSE THE IDENTIFIED CONFIDENTIAL INFORMATION IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR...Clinical Trial Research Agreement • January 25th, 2022 • Incannex Healthcare LTD • Pharmaceutical preparations
Name of Institution: Alfred Health a body corporate established under the Health Services Act 1988 (Vic) of Commercial Road, Melbourne, 3004 or Alfred Health
Clinical Trial Research Agreement New Zealand Association of Clinical Research (NZACRes) - Collaborative or Cooperative Research Group (CRG)Clinical Trial Research Agreement • March 23rd, 2021
This Agreement is to be used where; a Collaborative or Cooperative Research Group acts as, and assumes all of the agreed responsibilities of a Sponsor, as defined by the current Committee for Proprietary Medicinal Products (CPMP)/International Conference on Harmonisation (ICH) Note for Guidance on Good Clinical Practice (CPMP/ICH/135/95); and the approved Ethics Committee is satisfied that the Study will not be carried out principally for the benefit of the Manufacturer or distributor of the Investigational Product in question. See the Guidance Document for additional information. The body of this Agreement (that is from the following page to the execution clauses) is intended to be identical to the standard form, a copy of which is located at www.nzacres.org.nz. Any textual change to the body of this Agreement is to be ignored, and referenced instead to the standard form, as amended by Schedule 5 by way of Special Conditions. Where there is conflict between the main body of th
CLINICAL TRIAL RESEARCH AGREEMENT SMLOUVA O PROVEDENÍ KLINICKÉHO HODNOCENÍClinical Trial Research Agreement • April 5th, 2022
Penn Standard Clinical Trial Agreement ORS 04-2011 Clinical Trial Research Agreement (Sponsor Protocol for Phase 1)Clinical Trial Research Agreement • May 5th, 2020 • Pennsylvania
This Agreement is entered into by and between: The Trustees of the University of Pennsylvania, with an address at Office of Research Services, P-221 Franklin Building, 3451 Walnut Street, Philadelphia, PA 19104-6205, hereinafter called "Institution," through its Department of _______________________, and __________________________________________________ a corporation with its principal office and place of business at______________________________________, hereinafter called "Sponsor." The Institution and
ContractClinical Trial Research Agreement • December 1st, 2017
CLINICAL TRIAL RESEARCH AGREEMENT(For Use in the Czech Republic with a CRO) This Agreement is entered into as of the last date on the signature page hereof, by and between Health Care Service Provider THOMAYEROVA NEMOCNICE, Vídeňská 800, 140 59 Praha 4, Czech Republic, ID 00064190, VAT ID: CZ00064190, StateContribution Organization set up by the Ministry of Health of the Czech Republic, Full Text of the Foulding File No. MZDR 17268-IV/2012, registered in the Commercial Register kept by the Municipal Court in Prague, section Pr, file 1043 bank details Česká národní banka, account number XXX, represented by doc. MUDr. Zdeněk Beneš, CSc., director(hereinafter called "Provider) andCOVANCE, INC. 206 Carnegie Center Princeton NJ, 08540 USA hereinafter called "CRO" whom MERCK SHARP & DOHME CORP. with its address at 1 Merck Drive, Whitehouse Station, New Jersey 08889 USA, hereinafter called "Sponsor" has contractually engaged as a contract research organization concerning the management, fundi
ContractClinical Trial Research Agreement • January 6th, 2017
CLINICAL TRIAL RESEARCH AGREEMENT(For Use in the Czech Republic) This Agreement is entered into as of the last date on the signature page hereof, by and between FAKULTNÍ NEMOCNICE PLZEŇ, Edvarda Beneše 1128/13,Plzeň Zip code: 305 99, company Id. 00669806, Tax ID: CZ00669806, XXX, represented by MUDr. Václav Šimánek, Ph.D., executive director (hereinafter called "Provider of Medical Services") and MERCK SHARP & DOHME, s.r.o., with its address at Evropská 2588/33a, Prague 6, ZIP code 160 00, ID: 284 62564, tax ID: CZ 284 62 564, registered in the Companies Register maintained by the Municipal Court in Prague (Section C, File No. 143297), autorized representative Piotr Miekus, Executive Director, acting in its own name at the request of Merck Sharp & Dohme Corp. with its address at 1 Merck Drive, Whitehouse Station, New Jersey 08889, United States of America (hereinafter called "Sponsor") and XXX (hereinafter called “Principal Investigator”). SMLOUVA O PROVEDENÍ KLINICKÉHO HODNOCENÍ(Pro p
ContractClinical Trial Research Agreement • May 9th, 2017
CLINICAL TRIAL RESEARCH AGREEMENT (For Use in the Czech Republic only in conjunction with Principal Investigator Contract for Work) This Agreement is entered into as of the last date on the signature page hereof, by and between FAKULTNÍ NEMOCNICE OLOMOUC, with address at I.P. Pavlova 185/6, Olomouc, Zip code 779 00, Czech Republic, company ID: 00098892, Tax ID: CZ00098892, bank details Česká národní banka, account number 36334811/0710, represented by Doc. MUDr. Roman Havlík, Ph.D., Director (hereinafter called "Institution") and MERCK SHARP & DOHME, s.r.o., with its address at Evropská 2588/33a, Prague 6, Zip code 160 00, ID: 284 62 564, tax ID: CZ 284 62 564, registered in the Companies Register maintained by the Municipal Court in Prague (Section C, File No. 143294), bank details: CityBank Europe, plc. account number: 2051460102/2600 acting in its own name at the request of MERCK SHARP & DOHME CORP. with its address at 1 Merck Drive, Whitehouse Station, New Jersey 08889, Un
Clinical Trial Research Agreement and Indemnity Form Submission ChecklistClinical Trial Research Agreement • March 29th, 2023
Submission Instructions: Include the following detail in the submission email when providing clinical trial research agreements and documents to confirm clinical trial sponsor responsibilities and attach word versions of documents for review and signature.
ContractClinical Trial Research Agreement • September 26th, 2017
CLINICAL TRIAL RESEARCH AGREEMENT (For Use in the Czech Republic only in conjunction with Principal Investigator Contract for Work) This Agreement is entered into as of the last date on the signature page hereof, by and between FAKULTNÍ NEMOCNICE V MOTOLE, state contributory organization, with its address at V Úvalu 84, Prague 5, Zip code: 150 06, company ID: 00064203, Tax ID: CZ00064203, represented by XXX under a mandate dated 29 November 2016 (hereinafter called "Medical service provider") and Merck Sharp & Dohme, s.r.o., with its address at Evropská 2588/33a, Prague 6, ZIP code 160 00, ID: 284 62 564, tax ID: CZ 284 62 564, registered in the Companies Register maintained by the Municipal Court in Prague (Section C, File No. 143294), represented by Renan Özyerli, Managing Director, acting in its own name at the request of Merck Sharp & Dohme Corp. with its address at One Merck Drive, Whitehouse Station, New Jersey 08889, USA (hereinafter called "Sponsor"). SMLOUVA O PR
CLINICAL TRIAL RESEARCH AGREEMENT SMLOUVA O PROVEDENÍ VÝZKUMNÉHO KLINICKÉHO HODNOCENÍ This Clinical Trial Research Agreement (“Agreement”) is dated as of the date last indicated on the signature page below (“Effective Date”) by and among CSL Behring...Clinical Trial Research Agreement • March 28th, 2019
ContractClinical Trial Research Agreement • February 2nd, 2018
CLINICAL TRIAL RESEARCH AGREEMENT SMLOUVA O PROVEDENÍ KLINICKÉHO HODNOCENÍ This Clinical Trial Research Agreement (“Agreement”) is entered into as of 25 January 2018 and shall become effective upon the publishing of this executed Agreement in the Agreement Registry (“Effective Date”), by and among University Hospital Ostrava, with a place of business at 17. Listopadu 1790/5, 708 52 Ostrava-Poruba, Czech Republic, ID Number: 00843989, VAT Number: CZ00843989, TheFoundantion deed from 25th of November 1990, ref. OP- 054-25.11.90, In matters of this Agreement is authorized to act and sign: Josef Srovnal, M.D., deputy director for medical care, hereinafter called (“Institution”) and Prof. MUDr. Roman Hájek, CSc, with a place of business at University Hospital Ostrava, Hematooncology Clinic, 17.listopadu 1790, 708 52 Ostrava-Poruba, Czech Republic, hereinafter called (“Principal Investigator”) and Acerta Pharma B.V., with registered office at xxxxxxx, a Dutch limited liability company, rep
ContractClinical Trial Research Agreement • March 31st, 2017
CLINICAL TRIAL RESEARCH AGREEMENT No. 08/OVZ/16/064-P SMLOUVA O VÝZKUMNÉM KLINICKÉM HODNOCENÍ č.08/OVZ/16/064-P This Clinical Trial Research Agreement (“Agreement”) is entered into as of the date of signing by the last Party (“Effective Date”), by and among Fakultní nemocnice Ostrava, 17. listopadu 1790, 708 52 Ostrava, Czech Republic, Organization ID No.: 00843989, VAT Reg. No.: CZ00843989, person authorized to act and sign in respect of this Agreement: MUDr. Josef Srovnal, Deputy Director for Medical Care, Bank details: Česká národní banka, Na Příkopě 28, 115 03 Praha (Prague) 1, Account No.: 66332761/0710, IBAN: CZ59 0710 0000 0000 6633 2761,SWIFT: CNBACZPP, variable symbol for this study: 649071052 (“Institution”) and Prof. MUDr. Roman Hájek, CSc., with his place of work at Fakultní nemocnice Ostrava (University Hospital Ostrava), Klinika hematoonkologie (Clinic for Haematology and Oncology), 17. listopadu 1790, 708 52 Ostrava, Czech Republic (“Principal Investigator”)and Acerta Ph
CERTAIN CONFIDENTIAL INFORMATION IN THIS EXHIBIT WAS OMITTED BY MEANS OF MARKING SUCH INFORMATION WITH BRACKETS (“[***]”) BECAUSE THE IDENTIFIED CONFIDENTIAL INFORMATION IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR...Clinical Trial Research Agreement • January 25th, 2022 • Incannex Healthcare LTD • Pharmaceutical preparations
Study Name: Dose finding crossover trial investigating the effect of dronabinol combined with acetazolamide on Apnoea Hypopnea Index (AHI) in adults with obstructive sleep apnoea (OSA)
ContractClinical Trial Research Agreement • July 20th, 2017
Instructions: Insert your logo in the box to the left Resize logo by dragging right hand corner Update the footer information Delete these Instructions Complete other information in the Form
Clinical Trial Research Agreement Phase 4 Clinical Trial (Medicines) – Contract Research Organisation acting as Local SponsorClinical Trial Research Agreement • August 25th, 2020
This agreement is to be used where a Contract Research Organisation (CRO) acts as, and assumes all of the responsibilities of, a local commercial sponsor.
THIS SAMPLE IS PROVIDED AS A MODEL AGREEMENT AND SHOULD BE PROVIDED TO THE SPONSOR. CLINICAL TRIAL RESEARCH AGREEMENTClinical Trial Research Agreement • January 27th, 2021 • Louisiana
This Clinical Trial Research Agreement entered into this _______ day of ______________________ by and between the Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, herein represented by Louisiana State University Health Sciences Center – New Orleans (hereinafter "Institution") and _______________________________ (hereinafter "Sponsor") to conduct a study entitled: __________________________________________________________
Clinical Trial Research Agreement Information (Site Details):Clinical Trial Research Agreement • August 7th, 2018
Name of Approving Authority South Eastern Sydney Local Health District Approving Authority Contact Officer Mr Tobi Wilson Position General Manager, Prince of Wales, Sydney and Sydney Eye Hospitals and Health Services Contact Phone 0293823587 Contact Email SESLHD-RSO@health.nsw.gov.au
ContractClinical Trial Research Agreement • December 8th, 2016
CLINICAL TRIAL RESEARCH AGREEMENT(For Use in the Czech Republic) This Agreement is entered into as of the last date on the signature page hereof, by and between INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE, Vídeňská 1958/9, Zipcode: 140 21, Prague 4, Czech Republic, company ID: 00023001, Tax ID: CZ00023001 , bank details: represented by MUDr. Aleš Herman, Ph.D., director (hereinafter called "Institution") and Merck Sharp & Dohme, s.r.o., with its address at Evropská 2588/33a, Prague 6, ZIP code 160 00, ID: 28462 564, tax ID: CZ 284 62 564, registered in the Companies Register maintained by the Municipal Court in Prague (Section C, File No. 143294), acting in its own name at the request of Merck Sharp & Dohme Corp. with its address at One Merck Drive, Whitehouse Station, New Jersey 08889, USAAnd XXX(hereinafter called “Principal Investigator”) S MLOUVA O PROVEDENÍ K LINICKÉHO HODNOCENÍ(Pro použití v České republice) Tato smlouva je uzavřena ke dni, jehož datum je uvedeno jako pozděj
ContractClinical Trial Research Agreement • January 17th, 2018
AMENDMENT NO. 1 DODATEK Č. 1 This is an amendment Nr. 1 ("Amendment") to the Clinical Trial Research Agreement by and between Toto je dodatek č. 1 ("Dodatek") ke Smlouvě o provedení klinického hodnocení uzavřený mezi FAKULTNÍ NEMOCNICE KRÁLOVSKÉVINOHRADY, Šrobárova 1150/50, Prague 10, Zip code: 100 34, company ID: 00064173, Tax ID: CZ00064173, bank details Czech national bank, account number 16334101/0710, represented by Doc. MUDr.Robert Grill Ph.D. MHA, Director, Reference no.: KH46/2016, centre cost: 51029 (hereinafter called "Provider") FAKULTNÍ NEMOCNICÍ KRÁLOVSKÉVINOHRADY, Šrobárova 1150/50, Praha 10, PSČ: 100 34, bankovní spojení Ćeská národní banka, číslo účtu 16334101/0710, zastoupenou Doc. MUDr. Robertem Grillem, Ph.D. MHA, ředitelem, číslo jednací KH 46/2016, nákladové středisko: 51029 (dále jen "Poskytovatel") and a MERCK SHARP & DOHME, s.r.o., with its address at Na Valentince 3336/4, Prague 5, ZIP code 150 00, ID: 284 62 564, tax ID: CZ 284 62 564, registered in the Comp
Amendment to Clinical Trial Research Agreement (“Amendment”)Clinical Trial Research Agreement • May 25th, 2016
The Parties entered into a Clinical Trial Research Agreement, dated [insert effective date] in relation to clinical study, [insert study title and Protocol No.] (“Agreement”)
SWSLHDClinical Trial Research Agreement • January 18th, 2007
Research Ethics and Governance Manager – Jessica Grundy (oversee all office functions including HREC, Research Governance and Research Contracts)
CLINICAL TRIAL RESEARCH AGREEMENT SMLOUVA O PROVEDENÍ VÝZKUMNÉHO KLINICKÉHO HODNOCENÍClinical Trial Research Agreement • April 2nd, 2019
This Clinical Trial Research Agreement (“Agreement”) is dated as of the date defined in Section 11.1 of this Agreement by and among CSL Behring GmbH having its principal place of business at Emil-von-Behring-Str. 76, 35041 Marburg, Germany, VAT: DE 811111679 (“Sponsor”) and Nemocnice Na Homolce having its principal place of business address at Roentgenova 37/2, 150 30 Praha 5 - Motol, Czech Republic, VAT: CZ00023884(“Institution”) and XXXXXXXXXXXXXXXX. having its principal place of business address at Kardiologické oddělení, Nemocnice Na Homolce, Roentgenova 37/2, 150 30 Praha 5 - Motol, Czech Republic (“Principal Investigator”) collectively referred to as “the parties.” Tato smlouva o provedení výzkumného klinického hodnocení (dále jen „smlouva“) vstoupí v platnost, jak je definováno v článku 11.1 této smlouvy, a je uzavírána mezi společností CSL Behring GmbH se sídlem na adrese Emilvon-Behring-Str. 76, 35041 Marburg, Německo, DIČ: DE 811111679 (dále jen „zadavatel“) a Nemo
RESEARCH/CLINICAL TRIALS SERVICE AGREEMENTClinical Trial/Research Agreement • May 29th, 2019
This is a Clinical Trial/Research Agreement between NSW Health Pathology Prince of Wales Hospital and Client responsible for the Clinical Trial/Research, and relates to charges for pathology tests and services provided by NSWHP Prince of Wales Hospital to the Client.
New Zealand Association of Clinical Research Standardised Clinical Trial Research Agreement (sCTRA)Clinical Trial Research Agreement • November 8th, 2020
This Guidance Document relates to the standardised Clinical Trial Agreement (sCTRA) (version 5, dated 03 October 2016). The template document is to be used to facilitate agreement between the Sponsor and the Institution for clinical trials conducted in New Zealand. The body of the sCTRA is to be used without modification, in order to be accepted by NZ Institutions without the need for further legal review.
OFFICIALClinical Trial Research Agreement • April 15th, 2024
Regulatory requirements Multisite Clinical Trials Teletrials Contracts {Commercially sponsored trialso Medicines Australia C linical Trial Research Agreement (C TRA) {Investigator Initiated trialso Investigator Initiated CTRA for use in Victoria {Commercially sponsored tele trialso The Head Agreement between the Sponsor and the Institution (Primary Site) is the Medicines Australia Clinical Trial Research Agreement (CTRA). Schedule 1 should i nclude particulars of the Primary Site and Satellite Site(s). Schedule 2 should include additional teletrial -related costs in the budget as agreed, payments and invoicing, an d terms and conditions for the Satellite Site(s). When additional Satellite Sites join a cluster, the Sponsor should amend Schedules 1 and 2 of the CTRA.ando Medicines Australia Teletrials Subcontract between the Institution (Primary Site) and the subcontractor (Satellite Site) complements the Head Agreement. It should detail the management of clinical trial activities and fo
ContractClinical Trial Research Agreement • July 20th, 2017
Instructions: Insert your logo in the box to the left Resize logo by dragging right hand corner Update the footer information Delete these Instructions Complete other information in the Form
CLINICAL TRIAL RESEARCH AGREEMENT No. __________Clinical Trial Research Agreement • July 15th, 2009
This Agreement is entered into by and between the University of Texas ____________________ hereinafter called "Institution," and ____________________a corporation with its principle office and place of business at, _______________, hereinafter called "Sponsor."